BRIEF-Tango Therapeutics Announces First Patient Dosed In Phase 1/2 Trial Of Tng462 Plus Revolution Medicines’ Daraxonrasib
Reuters
Jun 27
BRIEF-Tango Therapeutics Announces First Patient Dosed In Phase 1/2 Trial Of Tng462 Plus Revolution Medicines’ Daraxonrasib
June 27 (Reuters) - Tango Therapeutics Inc TNGX.O:
TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL OF TNG462 PLUS REVOLUTION MEDICINES’ DARAXONRASIB OR ZOLDONRASIB IN PATIENTS WITH RAS-MUTANT MTAP-DELETED PANCREATIC OR LUNG CANCER
TANGO THERAPEUTICS INC - TNG462 MONOTHERAPY DATA EXPECTED IN SECOND HALF OF 2025
Source text: ID:nGNX4YxcC5
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.